ReviewNeuropsychiatric disease and treatment2015
Major depressive disorder: mechanism-based prescribing for personalized medicine.
Review in Neuropsychiatric disease and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Adjunctive brexpiprazole in patients with unresolved symptoms of depression on antidepressant treatment who are early in the disease course: post hoc analysis of randomized controlled trials.The international journal of neuropsychopharmacology · 2025Trial
- Results from a long-term open-label extension study of adjunctive buprenorphine/samidorphan combination in patients with major depressive disorder.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Trial
- Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial.European archives of psychiatry and clinical neuroscience · 2016Trial
- Patterns of antidepressant treatment changes among adults with major depressive disorder in Northwest Ethiopia: a hospital-based cross-sectional study.Therapeutic advances in psychopharmacology · 2026Article
- Development of erectile dysfunction in men treated for major depressive disorder with selective serotonin reuptake inhibitors: a systematic review.Archives of medical science : AMS · 2026Review
- The Pathogenesis and Medical Treatment of Depression: Opportunity and Challenge.Neurology international · 2025Review
- The GPR39 Receptor Plays an Important Role in the Pathogenesis of Overactive Bladder and Corticosterone-Induced Depression.International journal of molecular sciences · 2024Article
- Childhood adversity and the cortisol awakening response in depression: A meta-analysis.Journal of mood and anxiety disorders · 2023Article
- Predictive biosignature of major depressive disorder derived from physiological measurements of outpatients using machine learning.Scientific reports · 2023Article
- α7 Nicotinic acetylcholine receptor: a key receptor in the cholinergic anti-inflammatory pathway exerting an antidepressant effect.Journal of neuroinflammation · 2023Review
- Prevalence of depressive symptoms and their associated factors among older adults in Yirgalem town, Southern Ethiopia: A community-based cross-sectional study.Frontiers in psychiatry · 2023Article
- An Observational Pilot Study using a Digital Phenotyping Approach in Patients with Major Depressive Disorder Treated with Trazodone.Frontiers in psychiatry · 2023Article
- Regional homogeneity alterations of resting-state functional magnetic resonance imaging of chronic rhinosinusitis with olfactory dysfunction.Frontiers in neuroscience · 2023Article
- Long-Term Treatment with Trazodone Once-A-Day (TzOAD) in Patients with MDD: An Observational, Prospective Study.Neuropsychiatric disease and treatment · 2023Article
- Patient-reported outcome measures for life engagement in mental health: a systematic review.Journal of patient-reported outcomes · 2022Review
- Mindfulness-Enhanced Computerized Cognitive Training for Depression: An Integrative Review and Proposed Model Targeting the Cognitive Control and Default-Mode Networks.Brain sciences · 2022Review
- Aberrant functional connectivity in insular subregions in somatic depression: a resting-state fMRI study.BMC psychiatry · 2022Article
- Subgrouping time-dependent prescribing patterns of first-onset major depressive episodes by psychotropics dissection.World journal of psychiatry · 2021Article
- Geriatric depression and quality of life in North Shoa Zone, Oromia region: a community cross-sectional study.Annals of general psychiatry · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Individual patients with depression present with unique symptom clusters - before, during, and even after treatment. The prevalence of persistent, unresolved symptoms and their contribution to patient functioning and disease progression emphasize the importance of finding the right treatment choice at the onset and the utility of switching medications based on suboptimal responses. Our primary goal as clinicians is to improve patient function and quality of life. In fact, feelings of well-being and the return to premorbid levels of functioning are frequently rated by patients as being more important than symptom relief. However, functional improvements often lag behind resolution of mood, attributed in large part to persistent and functionally impairing symptoms - namely, fatigue, sleep/wake disturbance, and cognitive dysfunction. Thus, patient outcomes can be optimized by deconstructing each patient's depressive profile to its component symptoms and specifically targeting those domains that differentially limit patient function. This article will provide an evidence-based framework within which clinicians may tailor pharmacotherapy to patient symptomatology for improved treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.